Medeze Group

Medeze Group FCF Yield

The Free Cash Flow Yield of Medeze Group (MEDEZE.BK) as of Oct 27, 2026 is -0.22 %. In the previous year, Free Cash Flow Yield was 0.42 % — a change of -152.53% (lower).

FCF Yield

-0.22 %

YoY

-152.53%

Last updated:

Free Cash Flow Yield of Medeze Group is 2025 -0.22 % . Free Cash Flow Yield of Medeze Group was 2024 0.42 % . It decreases by -152.53% lower compared to the previous year.

The Medeze Group FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
2.66 THB
Jan 1, 2019
2.18 THB
Jan 1, 2020
1.49 THB
Jan 1, 2021
1.51 THB
Jan 1, 2022
3.34 THB
Jan 1, 2023
3.83 THB
Jan 1, 2024
0.42 THB
Jan 1, 2025
-0.22 THB
The Medeze Group FCF Yield history
YEARFCF YieldYoY
-0.22 %-152.53%
0.42 %-89.01%
3.83 %+14.73%
3.34 %+121.58%
1.51 %+1.00%
1.49 %-31.76%
2.18 %-17.84%
2.66 %-27.87%
3.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group Stock analysis

What does Medeze Group do? Medeze Group PLC operates as a mesenchymal stem cell bank in Thailand, offering stem cell storage services from umbilical cord tissue and adipose tissue, alongside umbilical cord blood storage. The company provides stem cell analysis, separation, cultivation, and storage services, including immune cell potential testing for Natural killer cells. Its white blood cell potential testing service segment evaluates NK cell performance and count, while the other services segment delivers research, data collection on human cellular activities, and medical laboratory tests. The sales of products segment generates revenue through dietary supplements, cosmetics, and dermo cosmetics. The company's primary customers are individuals seeking stem cell storage for future medical use, as well as those requiring immune cell testing and research services. The stem cell sample collection service segment targets expectant parents and medical institutions for cord blood and tissue storage. The white blood cell potential testing service segment serves healthcare providers and patients interested in NK cell analysis. The sales of products segment appeals to consumers purchasing dietary supplements and cosmetic products. Medeze Group PLC's revenue streams are derived from multiple segments: stem cell storage services, immune cell testing, research and laboratory services, and product sales. The stem cell sample collection and storage services form the core offering, while the white blood cell potential testing and other services provide additional value. Product sales contribute to revenue through the distribution of dietary supplements, cosmetics, and dermo cosmetics, targeting both individual consumers and healthcare-focused markets. Medeze Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeze Group stock

Free Cash Flow Yield of Medeze Group is -0.22 % in 2025.

Free Cash Flow Yield of Medeze Group changed from 0.42 % to -0.22 %, representing a -152.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Medeze Group since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Medeze Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medeze Group

All Key Metrics — Medeze Group